Brief: Acorda Therapeutics Reports First Quarter 2023 Financial Results
11/05/2023 21:44
May 11 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
* ACORDA THERAPEUTICS INC - 2023 FINANCIAL GUIDANCE
REAFFIRMED
* ACORDA THERAPEUTICS INC QTRLY LOSS PER SHARE $0.69
* ACORDA SEES 2023 INBRIJA U.S. NET REVENUE TO BE $38 - $42
MILLION, AMPYRA NET REVENUE TO BE $65 - $70 MILLION
* ACORDA THERAPEUTICS INC SEES 2023 ADJUSTED OPEX TO BE $93
- $103
MILLION
* ACORDA THERAPEUTICS INC - AGREEMENT WITH CHANCE
PHARMACEUTICALS
TO COMMERCIALIZE INBRIJA IN CHINA
Source text for Eikon: ID:nBwb6gQsLa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease